IMKELDI
Growthimatinib oral
NDAORALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
IMKELDI (imatinib oral) is protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the philadelphia chromosome abnormality in cml. First approved in 2024.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMKELDI is an oral solution formulation of imatinib, a protein-tyrosine kinase inhibitor targeting BCR-ABL in chronic myeloid leukemia (CML) and c-Kit in gastrointestinal stromal tumors (GIST). It works by inhibiting abnormal tyrosine kinases that drive cancer cell proliferation and inducing apoptosis in leukemic and tumor cells. This represents a new dosage form of an established mechanism with potential for improved patient compliance.
Growth14.0 years to LOE
Recent 2024 approval signals an active growth phase with opportunity for market penetration, though current job openings and team expansion data are not yet populated.
Mechanism of Action
protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IMKELDI offers entry-level to mid-career professionals the opportunity to build expertise in oncology commercialization during a critical launch phase, with a 14-year runway providing long-term stability. The formulation innovation angle provides differentiation messaging for MSLs and field teams, though lack of current job postings suggests the team may still be forming or scaling incrementally.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.